Medtronic wins FDA nod for SynchroMedII myPTM drug therapy manager

Medtronic (NYSE:MDT) said today that the FDA approved its new SynchroMedII myPTM personal therapy manager intended for use in treating patients with chronic pain.
The newly cleared device works with the company’s SynchroMedII intrathecal drug delivery system and is designed to handle delivering on-demand boluses within therapeutic limits set by physicians, the Fridley, Minn.-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post Medtronic wins FDA nod for SynchroMedII myPTM drug therapy manager appeared first on MassDevice.

Source: Mass Device - October 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Regulatory/Compliance Medtronic Source Type: news